HealthAsyst | March 01, 2021
A well-known healthcare technology solutions provider, HealthAsyst is happy to announce that it has now become an App Orchard contributor. App Orchard platform by HealthAsyst made communication and patient intake platform available to the Epic user community.
According to the CEO of HealthAsyst, Umesh Bajaj, they are very excited to make it available to Epic users. It makes sure the large user base of the company makes the advantage to their benefit to ensure a convenient and safe intake and enhance patient engagement during the pandemic and beyond.
CheckinAsyst is aimed at increasing the patient experience by providing them streamlined intake workflows and convenient communication options. It will make the process of paying outstanding balances and checking in simple. The app has got many features that makes it unique.
Since 1999, HealthAsyst is providing advanced solutions to the worldwide healthcare industry. The SOC 2 Type II compliant organization is focused on enhancing patient experience, operational efficiency, and care quality. App Orchard and Epic are part of Epic Systems Corporation and registered trademarks of the company
Luna | November 11, 2021
Luna, the leading provider of on-demand physical therapy, today announced a partnership with Airrosti, a national provider of high-quality, outcome-based musculoskeletal (MSK) care, to offer in-person, at-home physical therapy services to complement the Airrosti Remote Recovery (ARR) virtual care solution. Using Luna's in-person, on-demand physical therapy services platform, Airrosti can immediately expand access to convenient, high-quality, at-home care for patients in the 46 states currently covered by ARR.
The primary challenge faced by purely digital MSK offerings today lies in care coordination. No two patients are alike, and while many respond well to a virtual clinic experience, others require in-person care. However, for many patients, travelling to a clinic consistently for an extended period is inconvenient––or even impossible. For these patients and in markets where Airrosti doesn't have clinics, the Airrosti and Luna partnership is particularly important.
"As a provider group who is delivering care nationally, we needed a partner solution to best serve our virtual patients that may require in-person conservative care or physical therapy," said Chris Cato, D.C., chief population health officer for Airrosti. "This alliance with Luna provides timely and efficient access to high-quality care that improves clinical efficacy and drives better outcomes. And, from a service delivery standpoint, this relationship significantly enhances Airrosti's ability to rapidly ramp up in-person service in new markets as requested by our carrier and employer partners."
As an extension of Airrosti Remote Recovery, patients will gain the opportunity to use Luna's technology platform to request an appointment and then be matched to a local therapist based on specialty, geography, schedule, and other factors. Through the Luna partnership, ARR patients can expect:
To begin treatment within 48 hours of referral
In-person delivery at the patient's home, gym, or office
45 to 55 minutes of dedicated 1:1 time with a licensed physical therapist per visit
Comprehensive MSK treatment––Luna's model of care supports 87%+ of all patients needing outpatient physical therapy
A 50% higher adherence rate than in-clinic PT visits
"Airrosti recognizes that virtual care––and especially physical therapy––requires a customized, patient-centric approach to help improve outcomes. The hybrid virtual/in-person model made possible by this partnership will not only expand access to safe, convenient, high-quality care for more people nationwide, but will help ensure that more patients complete their PT regimens and regain the quality of life they need."
Palak Shah, co-founder and head of clinical operations at Luna
To learn more about Airrosti's virtual MSK offerings, visit the Remote Recovery resource page. For more information on how Luna helps clinics expand the reach and profitability of their operations, visit the Physical Therapy Practices resource page.
Airrosti Rehab Centers (Airrosti), is a national health care group that employs and trains skilled providers who specialize in delivering high-quality, outcome-based musculoskeletal care, both in person and virtually through their digital healthcare solution, Airrosti Remote Recovery (ARR). Airrosti Remote Recovery is the only virtual MSK solution supported by a provider group with over 1 million patient outcomes and 17 years of clinical experience. The company's strict adherence to quality care standards across its provider network significantly reduces costs and recovery times for patients and prevents unnecessary MRIs, pharmaceuticals, and surgeries. Many patients experience significant improvement in pain, range of motion, and a return to normal activity, often within only three visits (Based on patient-reported outcomes). Airrosti is currently available in 46 states including the District of Columbia and has over 200 brick-and-mortar locations across Texas, Virginia, Ohio, and Washington.
Luna is the leader in on-demand physical therapy, delivering outpatient physical therapy beyond the four walls of a clinic. For patients, Luna has reimagined the physical therapy experience, matching them with a therapist for in-person care at the time and location of their choosing and ongoing coaching through an easy-to-use app. For physical therapists, Luna enables them to manage their careers with flexibility and autonomy, using a platform that makes scheduling efficient, documentation easy, and billing automatic. Luna is the fastest growing in-person physical therapy provider, with more than 1,200 exceptional therapists providing services in 20 states across the United States.
Lucira Health | December 27, 2021
Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced a new agreement with Switch Health Solutions Inc. ("Switch Health") to increase Canadians' access to at-home molecular COVID-19 tests as Omicron cases surge. Lucira will provide more than 2 million at-home COVID-19 test kits in 2022 as part of the deal.
"As Omicron cases surge around the world, the need for better testing solutions has never been more apparent. Only Lucira's tests provide a PCR-quality test result in 30 minutes, wherever you are, from a simple, single-use kit. Making these tests more available is critical to help slow the spread of COVID-19."
Erik Engelson, President and Chief Executive Officer of Lucira
Switch Health is a Canadian healthcare company dedicated to providing better decentralized patient care. Switch Health has quickly become a leader in COVID-19 testing on-site at its Switch Health Clinics and at-home through its remote telehealth service and in-person visits.
"Switch Health's ability to be a Canadian health care leader in decentralized diagnostics is in large part due to the innovative technologies we make available to everyday Canadians," added Marc Thomson, Chief Operating Officer at Switch Health. "Lucira has been an instrumental partner in helping Switch Health achieve that in the COVID-19 era. Together, we are removing barriers to get Canadians safely back to work and reunited with their loved ones."
Last month, Lucira announced confirmation that its COVID-19 Check-It (OTC) and All-In-One (Rx) molecular self-test kits' can detect 100% of Omicron variant genome sequences analyzed, including the "stealth variant." Lucira assays target viral sequence regions unaffected by the spike protein mutations found in Omicron, Delta, and other variants of concern, allowing it to maintain its accuracy in the face of an evolving virus.
Lucira has received Interim Order authorization from Health Canada to sell and distribute its COVID-19 test kits for at-home self-testing in Canada.
LUCIRA™ CHECK IT Test Kit
The Lucira™ Check-It (OTC) and All-in-One (Rx) test kits are Nucleic-Acid Amplification Tests (referred to as NAAT). The tests fit in the palm of your hand, extract genetic material from the virus and amplify it, similar to PCR lab tests, to detect the presence of virus earlier and more accurately than antigen tests. The test uses an approach called reverse transcriptase loop-mediated isothermal amplification (RT-LAMP). It was designed and tested extensively for individuals to use independently and does not require a physician's prescription or supervised assistance. There is no additional equipment to purchase, such as a reader or instrument.
Each Lucira test kit contains everything needed to run one COVID-19 test. Users get the test device, two AA batteries, sample vial, swab and simple instructions. The batteries are inserted into the device and the sample vial is placed in the test unit. The user then opens the test swab packet and rotates the swab five times in each nostril. The swab is then stirred in the sample vial, which is then gently pressed into the test unit to start the test. The "ready" light will blink until a "positive" or "negative" green light is illuminated within 30 minutes. In the US, Lucira also offers a free LUCI Pass™ digital verified test result back to a user's phone. LUCI Pass is accessed via text and does not require downloading an app. There is also an opt-in for public health reporting for users who wish to transmit their results to the relevant public health authorities.
In clinical trials, 100% of users successfully performed the test at home in about two minutes using Lucira's easy-to-use 'swab, stir and detect' Check-It test kit.
In a Community Trial setting, Lucira™ Check-It results were compared with the Hologic Panther Fusion, considered a high-sensitivity molecular test due to its low Limit of Detection ("LOD"). Lucira's accuracy was 98%, correctly detecting 385 out of 394 positive and negative samples in comparison to the Hologic Panther Fusion, excluding ten samples with very low levels of virus (those with very high PCR cycle thresholds of 37.5 or greater) that possibly no longer represented active infection. Comparative positive results agreed 97% of the time among this sample, and negative results agreed 98% of the time.
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira's testing platform produces lab quality molecular testing in a single-use, consumer-friendly, palm-size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable, and on-the-spot molecular test results anywhere and at any time. The Lucira™ Check-It COVID-19 Test Kit (OTC) and Lucira™ COVID-19 All-In-One Test Kit (Rx) are designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection.